Calcium Channel Blocker (Dihydropyridine)Not Controlled

Norvasc®

Amlodipine Besylate

Generic (originally Pfizer)·FDA 1987·
2.5mg5mg10mg

Version 2025-04 · Last reviewed April 1, 2025 · Methodology

List Price

$30

With Insurance

$4

The Short Version

Plain-language summary

Norvasc (Amlodipine Besylate) relaxes the muscles in your blood vessel walls, letting them widen. This lowers blood pressure and improves blood flow to the heart.

How it works: Amlodipine blocks L-type calcium channels in vascular smooth muscle cells. When calcium cannot enter the muscle cells, the blood vessel walls relax and widen — lowering blood pressure. It is highly selective for blood vessels (not heart muscle), which is why it does not slow heart rate the way some other calcium channel blockers do.

What people most commonly report

Peripheral edema (ankle swelling)
10-15%
Headache
7%
Fatigue
5%
Dizziness
3-4%
Flushing / warmth
3%

Dose-dependent; most common at 10mg. Not heart failure — it is local vasodilation. Leg elevation helps.

Some studies were independent, others were paid for by the company that makes it.

What Else the Evidence Supports

Non-drug options with clinical backing

Weight loss, alcohol reduction, and eliminating ultra-processed foods appear to be among the most potent lifestyle levers for blood pressure — with effects comparable to first-line medications in some patients.

Weight lossEmerging

Approximately −1 mmHg systolic per kg lost; larger reductions with significant excess weight.

DASH diet patternEmerging

−8 to −14 mmHg systolic in hypertensive patients.

Aerobic exerciseEmerging

−5 to −8 mmHg systolic average.

Alcohol reductionEmerging

−4 to −7 mmHg systolic when reducing from moderate to low/none.

What This Really Costs

Long-term cost projection based on current pricing

Monthly

$15

$4 w/ insurance

without insurance

Annual

$180

$48 w/ insurance

without insurance

10 Years

$1.8K

$480 w/ insurance

without insurance

30 Years

$5.4K

$1.4K w/ insurance

without insurance

Lifestyle alternative: $0/month in prescriptions. Weight lossApproximately −1 mmHg systolic per kg lost; larger reductions with significant excess weight.

The average American retiree spends $165,000 on healthcare after retirement (Fidelity, 2024). Informed choices today compound over decades.

Related Evidence

Explore related medications reviewed on EvidentMeds

Metabolic & Lifestyle Alternatives

Lifestyle Approaches for Blood Pressure

Weight loss, alcohol reduction, and eliminating ultra-processed foods appear to be among the most potent lifestyle levers for blood pressure — with effects comparable to first-line medications in some patients.

Important context: Evidence quality varies across these approaches. Some are well-studied with randomized controlled trial data; others are based on observational or smaller studies. These interventions are not guaranteed to replace medication for all patients. Discuss with your doctor whether any of these are appropriate for your clinical situation.

Global Prescribing & Pricing

Amlodipine is the most prescribed antihypertensive globally — used as first-line in virtually every country

🇺🇸

United States

$30-60/mo

Rate

Most prescribed blood pressure medication overall

Policy

No lifestyle prerequisite required before prescribing

Cover

Usually covered

🇬🇧

United Kingdom

~$1-4/mo

Rate

NICE first-line for hypertension in patients over 55 or Black patients of any age

Policy

Lifestyle advice mandated alongside prescribing

Cover

Fully covered by NHS

🇫🇷

France

~$2-6/mo

Rate

Standard first-line per HAS guidelines

Policy

Lifestyle counseling reimbursed as part of care pathway

Cover

Covered by Sécurité Sociale

🇩🇪

Germany

~$4-10/mo

Rate

First-line alongside lifestyle emphasis

Policy

Lifestyle intervention emphasized per DHL guidelines

Cover

Covered by GKV

🇯🇵

Japan

~$8-20/mo

Rate

Most prescribed antihypertensive in Japan — preferred over ACE inhibitors due to lower cough rates

Policy

Strict BP targets; dietary programs promoted

Cover

Covered by JHIS

Amlodipine is the most prescribed blood pressure medication in the world — a genuine global consensus drug. The US pays $30-60/month for a medication that costs $1-4 in the UK. The molecule is identical.

Clinical Trials & Funding

Understanding who funds research helps contextualize results. Industry-funded trials are not automatically invalid — they undergo the same FDA review — but declared conflicts and sponsor effects are worth knowing. All linked trials can be verified on ClinicalTrials.gov.

Key Efficacy Results

ALLHAT: Equivalent to lisinopril and chlorthalidone for primary outcomes; ASCOT-BPLA: Superiority over atenolol for stroke prevention

Referenced Studies

Each study shows its evidence level and Cochrane RoB-2 risk-of-bias rating — tap the bias badge for details.

Evidence & Transparency

Cochrane RoB-2 (Risk of Bias)

Badges reflect an editorial assessment using Cochrane's RoB-2 tool domains: randomization, intervention deviation, missing data, outcome measurement, and selective reporting. These are not certified Cochrane reviews. Learn more ↗

CMS Open Payments

Manufacturer payment disclosures are reported via the CMS Sunshine Act. Disclosure is legally required and does not imply bias or misconduct. Language uses "may," "suggests," or "appears" — never definitive clinical claims. CMS Open Payments ↗

Live Clinical Trials

Live from ClinicalTrials.gov · refreshed every 4 hours

Currently enrolling, active, and recently completed studies involving Amlodipine Besylate. Data is pulled directly from the U.S. National Library of Medicine.

Recent Research

Live from PubMed · peer-reviewed literature · refreshed every 4 hours

Most recently indexed clinical trials and systematic reviews mentioning Amlodipine Besylate in PubMed.

Source Documentation

Structured citations for referenced clinical trials

Each referenced trial is listed with its registry ID, funding source, and bias assessment. Use the copy button to generate a formatted citation.

TrialRegistry IDCite
ALLHAT (NIH)NCT00000542
ASCOT-BPLA (Pfizer)PMID:16154016
CAMELOT (Pfizer)NCT00049621

Bias ratings use Cochrane RoB-2 methodology. Editorial assessment — not a certified Cochrane review.

Our Methodology

Common Side Effects

While taking this medication, you may experience the following common side effects. We've included tips on how to manage them.

Peripheral edema (ankle swelling)

10-15%

Dose-dependent; most common at 10mg. Not heart failure — it is local vasodilation. Leg elevation helps.

Dizziness

3-4%

Usually in first week; rise slowly from sitting

Flushing / warmth

3%

Common early in therapy; resolves as body adjusts

Fatigue

5%

Often improves over first few weeks

Headache

7%

Usually mild and self-limiting in first week

Palpitations

1-4%

Reflex tachycardia from vasodilation — usually benign

Nausea

3%

Take with food if needed

Gum overgrowth (gingival hyperplasia)

2-3%

Good oral hygiene reduces risk; reversible if caught early

Serious Adverse Effects

  • Severe hypotension (especially with other antihypertensives)
  • Worsening angina or MI (rare, on initiation)
  • Hepatitis (rare)
  • Severe allergic reaction (angioedema — very rare)

Drug Interactions

Major Interactions (Avoid)

Simvastatin (high dose)Increases simvastatin levels — limit simvastatin to 20mg when combined
CyclosporineIncreases cyclosporine blood levels — monitor closely

Moderate Interactions (Caution)

Beta-blockersAdditive heart rate and blood pressure lowering — monitor for symptomatic bradycardia
CYP3A4 inhibitors (ketoconazole, erythromycin)May increase amlodipine levels and side effects
LithiumPossible neurotoxicity — monitor lithium levels

Food Interactions

Grapefruit juiceIncreases amlodipine blood levels modestly — clinically relevant in some patients
AlcoholAdditive blood pressure lowering; increased dizziness

When to Contact Your Doctor

This medication requires ongoing medical supervision. The following situations warrant a prompt conversation with your prescribing physician — do not wait for your next scheduled appointment.

Contact soon if you notice

  • Severe hypotension (especially with other antihypertensives)
  • Worsening angina or MI (rare, on initiation)
  • Hepatitis (rare)
  • Severe allergic reaction (angioedema — very rare)
  • Blood pressure rising above 140/90 mmHg

Also discuss if you want to

  • Review whether this medication is still appropriate for you
  • Consider dosage adjustments based on response
  • Explore lifestyle or non-drug alternatives
  • Understand stopping or tapering options
  • Plan monitoring labs and follow-up

In the US, call 911 or go to the nearest emergency room for severe symptoms. Poison Control: 1-800-222-1222.

Special Populations

Safety classifications for specific groups — discuss with your provider before use.

Not RecommendedPregnancy

Category C. Animal data suggest risk. Nifedipine is the preferred CCB in pregnancy.

Use With CautionBreastfeeding

Passes into breast milk in small amounts. Monitor infant for low blood pressure.

Blood Pressure Rises Post-MenopauseMenopause / Hormonal

Estrogen loss leads to vascular stiffness and rising blood pressure. Amlodipine is often prescribed to menopausal women because it works well regardless of age. Ask whether hormonal factors should be evaluated alongside blood pressure treatment.

Approved ≥6 yearsChildren & Teens

Approved for hypertension in children 6 and older. Start at 2.5mg.

Start LowOlder Adults

Start at 2.5mg. Greater sensitivity to hypotension. Edema risk increases with age.

No Adjustment NeededKidney Disease

Not renally cleared. Safe in kidney disease without dose changes.

FDA Adverse Event Reports

Patient-filed reports from the FDA FAERS database · refreshed daily

Anecdotal data. Reports are not confirmed causation. Always consult your provider.

Community Reports

User-reported experiences — anonymous & anecdotal

Stopping This Medication Safely

Taper CautiouslyDocumented timeframe: 2-4 weeks minimum

Abrupt discontinuation can cause rebound hypertension and worsening angina. Blood pressure may rise sharply within days of stopping.

What Published Research Shows About Stopping This Medication

This summarizes what published research documents — it is not personal medical advice. Any changes to your medication require discussion with your prescribing physician.

  • ·Research supports gradual dose reduction rather than abrupt cessation — particularly in patients with coronary artery disease
  • ·Published tapering approaches describe reducing from 10mg → 5mg → 2.5mg every 1-2 weeks
  • ·Home blood pressure monitoring twice daily is recommended throughout the tapering process
  • ·Building a whole-food dietary foundation before tapering (DASH pattern, exercise, weight management) improves success rates

Warning Symptoms — Contact Your Doctor If You Experience:

  • Blood pressure rising above 140/90 mmHg
  • Chest pain or pressure
  • Severe headache
  • Ankle swelling returning (may indicate need to resume)

Never change or stop a medication without consulting your prescribing physician.

Questions for Your Doctor

Questions to Ask

  • 1.Can lifestyle changes lower my blood pressure enough to avoid medication?
  • 2.Is amlodipine the best first-line choice for my age and background?
  • 3.What should I do about the ankle swelling — is it dangerous?
  • 4.Could I try a lower dose first?

Lab Tests to Request

  • Blood pressure log (home monitoring)
  • Kidney function (creatinine/BUN)
  • Electrolytes (potassium, sodium)
  • Liver function (if symptoms develop)

Medical Disclaimer

The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.

Get notified when we update Norvasc®

We'll email you when new evidence, safety updates, or alternatives are added.

No spam. Unsubscribe anytime.